[What is Practically Important when Carrying out a Chemotherapy?]

Overview

Journal Urologe A

Specialty Urology

Date 2006 Apr 20

PMID 16622643

Citations 4

Authors

M Schenck

T Jager

Affiliations

Soon will be listed here.

Abstract

The patient stands at the center of a chemotherapy. The aim of the curative or palliative treatment is not only the death of the tumor cells, but also the maintenance or improvement of the patient's physical condition, especially the improvement of quality of life. Before starting the therapy, it is necessary to determine, for example, the patient's general condition and motivation, and to carry out a consultation. Examinations, for example, blood tests, audiograms, renal function and lung function should also be made. Thus, the patient's tolerance for even the most onerous chemotherapy can be investigated and patients can be individually prepared for the treatment.

Citing Articles

Evaluation of complications of totally implantable central venous port system insertion.

Kim D, Ryu D, Jung H, Lee S Exp Ther Med. 2019; 17(3):2013-2018.

PMID: 30867691 PMC: 6395957. DOI: 10.3892/etm.2019.7185.

[How should urologists perform implantation of subcutaneous central venous port systems? A single center experience of 347 cases].

Schenck M, Michels-Oswald W, Tschirdewahn S, Rubben H, Dorp F, Rose A Urologe A. 2011; 51(2):226-37.

PMID: 21927874 DOI: 10.1007/s00120-011-2715-3.

Central venous port implantations via the cephalic vein applying an intravasal electrographic control of the catheter tip position: a single-center experience of 316 cases.

Schenck M, Schneider T, Rubben H, Eisenhardt A World J Urol. 2011; 30(3):399-404.

PMID: 21874511 DOI: 10.1007/s00345-011-0752-6.

[Urogenital symptoms and possibilities for urological intervention in the palliative care situation].

Jager T, Schenck M Urologe A. 2007; 46(10):1407-11.

PMID: 17874230 DOI: 10.1007/s00120-007-1548-6.

References

Bokemeyer C, Oechsle K, Hartmann J, Schoffski P, Schleucher N, Metzner B . Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer. 2002; 87(10):1066-71. PMC: 2376199. DOI: 10.1038/sj.bjc.6600629. View

de Wit R, Herrstedt J, Rapoport B, Carides A, Carides G, Elmer M . Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003; 21(22):4105-11. DOI: 10.1200/JCO.2003.10.128. View

Mir O, Alexandre J, Ropert S, Amsellem-Ouazana D, Flam T, Beuzeboc P . Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs. 2005; 16(9):1017-21. DOI: 10.1097/01.cad.0000176503.48433.74. View

Hesketh P, Van Belle S, Aapro M, Tattersall F, Naylor R, Hargreaves R . Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003; 39(8):1074-80. DOI: 10.1016/s0959-8049(02)00674-3. View

Roila F . Multinational Association of Supportive Cancer Care (MASCC). Support Care Cancer. 2003; 11(4):260-1. View

Hurria A, Hurria A, Brogan K, Panageas K, Pearce C, Norton L . Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging. 2005; 22(9):785-91. DOI: 10.2165/00002512-200522090-00007. View

Pizzo P . Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer. 1984; 54(11 Suppl):2649-61. DOI: 10.1002/1097-0142(19841201)54:2+<2649::aid-cncr2820541409>3.0.co;2-6. View

Chen C, Kenefick A, Tang S, McCorkle R . Utilization of comprehensive geriatric assessment in cancer patients. Crit Rev Oncol Hematol. 2004; 49(1):53-67. DOI: 10.1016/s1040-8428(03)00098-2. View

Aapro M . Optimising antiemetic therapy: what are the problems and how can they be overcome?. Curr Med Res Opin. 2005; 21(6):885-97. DOI: 10.1185/030079905X46313. View

10.

Rademaker-Lakhai J, Crul M, Zuur L, Baas P, Beijnen J, Simis Y . Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006; 24(6):918-24. DOI: 10.1200/JCO.2006.10.077. View

11.

Horstman M, Meadows G, Yost G . Separate mechanisms for procarbazine spermatotoxicity and anticancer activity. Cancer Res. 1987; 47(6):1547-50. View

12.

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

13.

Sauer H . [Systemic cytostatic chemotherapy]. Internist (Berl). 1998; 39(11):1104-14. DOI: 10.1007/s001080050281. View

14.

Cella D, Tulsky D, Gray G, Sarafian B, Linn E, Bonomi A . The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11(3):570-9. DOI: 10.1200/JCO.1993.11.3.570. View

15.

Grahmann P, Brauer M, Huter L, Sayer H, Neumann R, Braun R . [Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration]. Pneumologie. 2005; 59(11):763-9. DOI: 10.1055/s-2005-919069. View